leadf
logo-loader
viewDestiny Pharma PLC

Destiny Pharma has announced the appointment of Dr Stephanie Bewick as its chief business officer

Most recently, Bewick was vice president, Business Development at Summit Therapeutics, a NASDAQ-listed infectious disease company, leading the out-licensing and in-licensing activities, pipeline positioning and technology valuation

Destiny Pharma PLC -
Handshake

Destiny Pharma PLC (LON:DEST) has announced the appointment of Dr Stephanie Bewick as its chief business officer.

The clinical-stage innovative biotechnology company, which is focused on the development of novel medicines that can prevent life-threatening infections, noted that Dr Bewick brings 20 years' experience in business development at public and private biotech companies as well as mid-sized pharma, both in-house and as a consultant. 

Most recently, she was vice president, Business Development at Summit Therapeutics, a NASDAQ-listed infectious disease company, leading the out-licensing and in-licensing activities, pipeline positioning and technology valuation. She holds a BSc (Hons) Neuroscience from the University of Edinburgh and a PhD from the University of Bristol.

READ: Destiny Pharma completes enrolment for XF-73 trial on schedule

In a statement, Neil Clark, chief executive officer of Destiny Pharma, said: "I am very pleased to welcome Stephanie to Destiny Pharma. She brings a wealth of experience and a proven track record in business development and deal-making having completed a range of transactions including in the anti-infectives space. Her expertise will be invaluable to Destiny Pharma as we look to maximise the value of our two late-stage clinical assets and in building a world-leading anti-infection company."

Bewick added: "This is a very exciting time to join Destiny Pharma after such a transformational year. Destiny Pharma has a fantastic XF platform and biotherapeutic/microbiome pipeline with unique late-stage clinical assets. I look forward to working with Neil and the team to progress the vibrant pipeline."

On Tuesday, Destiny Pharma said its XF-73 Phase 2b clinical trial was fully recruited by the end of 2020, meeting the target timeline.

The company said results of the trial are expected in the first quarter of this year.

Quick facts: Destiny Pharma PLC

Price: 115.5 GBX

AIM:DEST
Market: AIM
Market Cap: £69.09 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Destiny Pharma PLC named herein, including the promotion by the Company of Destiny Pharma PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Destiny Pharma presents at the Proactive One2One live investment forum

  Destiny Pharma's (LON:DES) Neil Clark (CEO) pitches to investors at the Proactive One2One live virtual forum. Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its...

on 22/1/21

2 min read